BioCentury
ARTICLE | Finance

Qsymia sera

First Manhattan in charge of Qsymia after gaining control of Vivus board

July 22, 2013 7:00 AM UTC

Now that First Manhattan Co. is gaining control of Vivus Inc.'s board and the top management job, all eyes will be on whether the dissident shareholder's team can ramp up sales of obesity drug Qsymia. Neither party is talking after their proxy settlement, but incoming CEO Anthony Zook has a commercial background.

As part of the settlement, Vivus' board will be expanded to 11 members from nine. Seven will be proposed by First Manhattan and the other four will be existing Vivus directors...